Craig is Chief Architect at AT&T responsible for Strategy & Innovation and has 20 years’ experience in executive leadership / management, strategic planning, marketing, sales and support of advanced technologies solutions. He advises and educates executives and management on emerging technology trends and relevant business focused solutions. He has served as a startup mentor for ASU's W.P. Carey entrepreneurship classes and programs and for ASU's Office of Entrepreneurship & Innovation.
Wiley is Senior Program Manager for Arizona State University's Office of Entrepreneurship & Innovation. He manages commercialization assistance programs that include the ASU Startup Accelerator, the Furnace Technology Transfer Accelerator, and faculty research startup portfolio companies. He is an NSF I-Corps mentor, and serves on the advisory committee of the Arizona Diversification Initiative.
Hector Rieiro, CTO
Hector is a Ph.D. student in Information and Communications Technology at the University of Vigo in Spain. He has been a programmer, data analyst, and laboratory technician in the Laboratory of Behavioral Neurophysiology at Barrow Neurological Institute (BNI) in Phoenix, where he assisted Dr. Steven Macknik and Dr. Susana Martinez-Conde in the eye-tracking intellectual property licensed by Saccadous. He has spent the last six (6) years in the lab at BNI working with our inventors and earning his Ph.D. Hector is proficient in Object Oriented development, and has extensive application development experience in C/C++, Java and MATLAB. He has knowledge of Objective-C, Assembler, Python, OpenCL and SQL.
Susana Martinez-Conde, PhD, Director, Laboratory of Integrative Neuroscience, SUNY - Downstate Medical Center
Prof. Martinez-Conde received a BSc in Experimental Psychology from Universidad Complutense de Madrid and a PhD in Medicine and Surgery from the Universidade de Santiago de Compostela in Spain. She was a postdoctoral fellow with the Nobel Laureate Prof. David Hubel, and then an Instructor in Neurobiology, at Harvard Medical School. Previous to her current appointment in SUNY Downstate, she directed laboratories at University College London in the UK and at the Barrow Neurological Institute in Phoenix, Arizona. Her work with Parkinsonian patients was recently honored with the EyeTrack Award, a global science prize given to a single cutting-edge publication in eye movement research. Prof Martinez-Conde has received many other distinctions, including the Empire Innovator Award from the State of New York, and the “100 Spaniards” Prize. Prof. Martinez-Conde's research bridges perceptual, oculomotor, and cognitive neuroscience. Recent research into the oculomotor mechanisms of microsaccade generation has been instrumental to present understanding of saccadic and microsaccadic function. Studies by the Martinez-Conde lab and others have built a solid case that microsaccades and saccades share most, perhaps all, physical and functional properties and dynamics. The Martinez-Conde lab has shown strong interactions between saccade and microsaccade production, suggesting a common triggering mechanism and supporting the hypothesis of a shared saccade–microsaccade generator. Current work focuses in determining the mechanistic basis and specific circuits implied in microsaccade triggering, through eye movement recordings from patients suffering from neurological disease, and from healthy individuals, aided by computational modeling of the oculomotor pathways leading to microsaccade generation.
Stephen Macknik, PhD, Director, Laboratory of Translational Neuroscience, SUNY - Downstate Medical Center
Stephen L. Macknik is the Director of the Laboratory of Translational Neuroscience, and a Professor of Ophthalmology, Neurology, and Physiology & Pharmacology, at SUNY Downstate Medical Center in New York City. His lab works on fundamental questions in neurobiology including oculomotor neuroscience, perception, cognition, and advanced imaging of neural structures. His current research is funded by the National Science Foundation, the Department of Defense, and the US Marine Corps and US Army. A focus of current research is to apply advanced models of oculomotor function to measure drug use—such as marijuana and narcotics during the operation of motor vehicles—and neural disease—such as Alzheimer’s disease and Parkinson’s disease. Dr. Macknik has won several recent awards for his research and public outreach: he is an Empire Innovator Scholar (from New York State), he recently shared the EyeTrack Prize for the best paper in oculomotor research in the world, and the 2013 Research Initiative Award from The American Epilepsy Society. He co-authored the “Illusions” column for Scientific American Mind, and his book, Sleights of Mind won the 2013 Prisma Prize for Best Science Book of the Year. Stephen is among the premier science communicators in the United States and has appeared in dozens of television and radio appearances and hundreds of media stories all around the globe.
Ron King, Ph.D., MBA, Chief Science and Business Officer, BioAccel
Dr. King is the Chief Science and Business Officer as well as co-founder of BioAccel. Dr. King brings more than 23 years experience in health technology, business, and policy management in both public and private sectors. Prior to starting BioAccel, Dr. King was the Vice President of Business and Strategic Partnerships at The Translational Genomics Research Institute (TGen) where he was responsible for alliance management, business development, and technology commercialization. Dr. King has in depth experience in creating and launching novel programs designed to transform new technologies from research discoveries into useful products and business opportunities. Dr. King is an expert in developing and executing novel strategies for integrating science and business. Dr. King has held several senior level positions at the National Institutes of Health, including: Associate Director of Intramural Research and Director of Technology Transfer at the National Human Genome Research Institute. Dr. King helped manage the development of several technology programs associated with the Human Genome Project. He shared responsibility for over 300 scientists. Dr. King has extensive experience in academia, government, and industry. He has been involved at various levels in the formation and launch of over ten biotech companies and currently serves on the boards of three. Dr. King is an adjunct faculty member at the W.P. Carey School of Business at Arizona State University. He is also an adjunct faculty member at the Translational Genomics Research Institute. Dr. King holds a Ph.D. in Biochemistry and Pharmacology from the University of California, Los Angeles and Riverside. He holds an MBA from Arizona State University, and certifications and training from the Haas School of Business at the University of California, Berkeley.
Philip R. Shumway, MBA
Phil is an experienced business executive with over 35 years of experience in high technology sales, sales management, operations management, and C level involvement in Fortune 200 companies. He is currently President of Management Productivity Group, LLC, a Phoenix-based consultancy assisting small companies and entrepreneurs in their growth and strategic planning. His background includes engagements in sales management and operations management for Apple, Inc., where he last served in the mid-nineties as Director of Sales Operations for the U.S., supporting over $8 billion in revenue for 3 business divisions. Subsequent jobs included developing a server channel sales division for Unisys, serving as CEO of a small public company (Vitrix/Time America), Vice President of Sales/Western U. S. for Fujitsu Computer, and running a management training company. He has served on several charitable boards, including the Child Crisis Center, and Foundation Board for the same organization. He is a former USAF pilot, and retired Lt. Col (USAFR). He holds a B.S. in Management from Bowling Green State University, and an MBA from the University of Northern Colorado.